
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Kythera Biopharmaceuticals, Inc. (Calabasas, CA, www.kytherabiopharma.com), has appointed Patricia Walker, MD, PhD, as chief medical officer and vice president of clinical development and regulatory affairs.
Kythera Biopharmaceuticals, Inc. (Calabasas, CA,







